Sectors & Industries HealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
SNPX	SYNAPTOGENIX INC	United States	$5.21M	1,085,334	79.75%	20.25%
VOR	VOR BIOPHARMA INC	United States	$117.93M	68,168,771	87.43%	10.18%	Net Selling	Net Selling
THRD	THIRD HARMONIC BIO INC	United States	$459.26M	40,714,399	73.29%	26.71%	Net Buying	Net Buying
ELYM	ELIEM THERAPEUTICS INC	United States	$122.80M	27,719,409	60.80%	23.57%	Net Buying
SYRS	SYROS PHARMACEUTICALS INC	United States	$135.18M	26,453,891	46.94%	53.06%	Net Buying	Net Selling
PTIX	PROTAGENIC THERAPEUTICS INC	United States	$5.99M	4,435,132	2.55%	1.03%	Net Buying
SLNO	SOLENO THERAPEUTICS INC	United States	$1.23B	32,460,579	20.62%	79.38%	Net Buying	Net Selling
WVE	WAVE LIFE SCIENCES LTD	Singapore	$585.74M	122,284,139	61.18%	38.82%	Net Buying	Net Selling
CELC	CELCUITY INC	United States	$518.01M	30,453,120	52.40%	15.32%	Net Selling	Net Selling
CMPX	COMPASS THERAPEUTICS INC	United States	$210.51M	137,589,171	62.59%	12.24%	Net Buying	Net Selling
BCRX	BIOCRYST PHARMACEUTICALS INC	United States	$944.17M	206,149,929	83.05%	16.95%	Net Selling	Net Selling
TYRA	TYRA BIOSCIENCES INC	United States	$758.93M	52,521,050	59.50%	40.50%	Net Buying	Net Buying
AURA	AURA BIOSCIENCES INC	United States	$348.02M	49,504,405	74.74%	17.47%	Net Buying	Net Selling
XNCR	XENCOR INC	United States	$1.17B	61,120,272	66.74%	33.26%	Net Buying	Net Selling
IOVA	IOVANCE BIOTHERAPEUTICS INC	United States	$3.30B	279,307,043	16.06%	83.94%	Net Buying	Net Buying
MTNB	MATINAS BIOPHARMA HOLDINGS INC	United States	$41.76M	217,482,830	11.76%	13.73%
GERN	GERON CORP	United States	$2.01B	546,059,309	72.04%	1.23%	Net Buying
ONVO	ORGANOVO HOLDINGS INC	United States	$11.24M	10,040,074	4.53%	95.47%	Net Selling
INMB	INMUNE BIO INC	United States	$151.96M	18,026,473	12.71%	40.17%	Net Selling
CTMX	CYTOMX THERAPEUTICS INC	United States	$119.19M	67,721,658	48.20%	30.89%	Net Buying	Net Buying
PRAX	PRAXIS PRECISION MEDICINES INC	United States	$672.24M	13,238,349	40.09%	59.91%	Net Buying	Net Selling
ORGS	ORGENESIS INC	United States	$17.48M	34,338,782	4.00%	96.00%	Net Buying	Net Buying
GNLX	GENELUX CORP	United States	$97.12M	26,865,473	21.54%	5.21%	Net Selling
AFMD	AFFIMED NV	Germany	$79.64M	15,227,463	100.00%	0.00%
RGNX	REGENXBIO INC	United States	$756.60M	44,427,555	76.15%	23.85%	Net Selling	Net Buying
ABVX	ABIVAX SA	France	$936.38M	62,928,818	33.79%	0.00%
APM	APTORUM GROUP LTD	China	$37.57M	5,181,697	0.85%	40.28%
RCUS	ARCUS BIOSCIENCES INC	United States	$1.35B	90,864,829	48.32%	51.68%	Net Buying	Net Buying
TNGX	TANGO THERAPEUTICS INC	United States	$796.12M	106,718,315	59.42%	40.58%	Net Buying	Net Selling
SCPH	SCPHARMACEUTICALS INC	United States	$159.36M	36,054,409	56.17%	43.83%	Net Selling
PRQR	PROQR THERAPEUTICS NV	Netherlands	$154.57M	81,354,592	22.61%	0.00%
CDXC	CHROMADEX CORP	United States	$298.98M	75,309,118	8.22%	91.78%	Net Buying
SYBX	SYNLOGIC INC	United States	$20.62M	11,646,977	3.98%	96.02%	Net Selling	Net Selling
PHAT	PHATHOM PHARMACEUTICALS INC	United States	$573.08M	58,477,351	60.10%	39.90%	Net Selling	Net Selling
MGX	METAGENOMI INC	United States	$309.15M	37,472,351	0.00%	32.96%	Net Buying	Net Buying
CHRS	COHERUS BIOSCIENCES INC	United States	$242.34M	112,714,488	72.75%	18.69%	Net Buying	Net Buying
AUTL	AUTOLUS THERAPEUTICS PLC	United Kingdom	$1.29B	265,926,305	43.49%	0.00%
OABI	OMNIAB INC	United States	$559.86M	117,126,046	71.51%	26.39%	Net Buying	Net Buying
ELAB	ELEVAI LABS INC	United States	$9.93M	17,329,615	0.15%	99.85%
BYSI	BEYONDSPRING INC	United States	$72.18M	39,015,476	14.02%	0.00%
HRTX	HERON THERAPEUTICS INC	United States	$416.41M	150,328,585	48.57%	51.43%	Net Buying
IBRX	IMMUNITYBIO INC	United States	$3.53B	673,952,278	8.50%	7.94%	Net Buying	Net Selling
FBIO	FORTRESS BIOTECH INC	United States	$34.05M	19,234,526	24.35%	62.68%	Net Buying	Net Buying
GANX	GAIN THERAPEUTICS INC	United States	$51.58M	16,219,709	9.53%	2.11%	Net Buying	Net Buying
ADAP	ADAPTIMMUNE THERAPEUTICS PLC	United Kingdom	$244.10M	1,480,950,456	7.28%	92.72%	Net Selling
FTRE	FORTREA HOLDINGS INC	United States	$3.26B	89,400,000	99.87%	0.13%	Net Buying	Net Selling
INZY	INOZYME PHARMA INC	United States	$287.24M	61,771,977	54.64%	45.36%	Net Buying	Net Selling
CMMB	CHEMOMAB THERAPEUTICS LTD	Israel	$8.38M	284,094,700	0.99%	5.96%
SGMT	SAGIMET BIOSCIENCES INC	United States	$129.89M	31,913,887	39.98%	60.02%	Net Buying	Net Buying
RZLT	REZOLUTE INC	United States	$128.39M	39,625,271	21.83%	78.17%	Net Buying	Net Buying
FBRX	FORTE BIOSCIENCES INC	United States	$26.93M	36,394,882	51.83%	22.30%	Net Buying	Net Selling
SNTI	SENTI BIOSCIENCES INC	United States	$14.18M	45,755,021	25.05%	52.51%
ALXO	ALX ONCOLOGY HOLDINGS INC	United States	$806.45M	50,152,082	75.60%	24.40%	Net Selling	Net Selling
IMRX	IMMUNEERING CORP	United States	$54.47M	29,283,272	53.75%	46.25%	Net Selling	Net Selling
ADCT	ADC THERAPEUTICS SA	Switzerland	$409.35M	82,529,549	41.10%	37.51%
MLTX	MOONLAKE IMMUNOTHERAPEUTICS	United States	$2.78B	63,886,757	72.47%	27.53%	Net Buying	Net Selling
ALVR	ALLOVIR INC	United States	$86.96M	114,869,175	14.62%	85.38%	Net Buying	Net Selling
MURA	MURAL ONCOLOGY PLC	Ireland	$63.63M	16,922,550	78.93%	2.66%
GOSS	GOSSAMER BIO INC	United States	$184.98M	225,582,250	86.47%	13.53%	Net Buying	Net Selling
CTNM	CONTINEUM THERAPEUTICS INC	United States	N/A	27,055,790	0.00%	9.96%
MIRA	MIRA PHARMACEUTICALS INC	United States	$11.97M	14,780,885	0.66%	30.26%	Net Buying
TRML	TOURMALINE BIO INC	United States	$427.78M	25,646,509	43.00%	57.00%	Net Selling	Net Buying
IPA	IMMUNOPRECISE ANTIBODIES LTD	Canada	$33.42M	26,315,260	6.56%	0.00%
SRZN	SURROZEN INC	United States	$29.94M	3,198,786	5.92%	94.08%	Net Buying	Net Buying
RCKT	ROCKET PHARMACEUTICALS INC	United States	$2.14B	90,504,248	54.89%	45.11%	Net Selling	Net Selling
APVO	APTEVO THERAPEUTICS INC	United States	$380.36k	533,464	34.00%	66.00%
ACHL	ACHILLES THERAPEUTICS PLC	United Kingdom	$33.48M	41,082,948	53.02%	0.00%
RLMD	RELMADA THERAPEUTICS INC	United States	$141.22M	30,174,202	45.13%	3.43%	Net Buying	Net Buying
ELEV	ELEVATION ONCOLOGY INC	United States	$201.42M	48,651,115	53.13%	24.22%	Net Selling	Net Selling
CRVS	CORVUS PHARMACEUTICALS INC	United States	$66.69M	49,038,582	39.12%	60.38%	Net Buying
HEPA	HEPION PHARMACEUTICALS INC	United States	$11.66M	5,472,451	7.54%	92.46%	Net Buying
CRGX	CARGO THERAPEUTICS INC	United States	$767.58M	39,363,052	71.34%	28.66%	Net Buying
THTX	THERATECHNOLOGIES INC	Canada	$61.61M	45,980,019	33.01%	0.00%
TARA	PROTARA THERAPEUTICS INC	United States	$31.21M	11,433,837	11.95%	88.05%	Net Selling	Net Selling
VRPX	VIRPAX PHARMACEUTICALS INC	United States	$4.06M	1,171,233	4.26%	95.74%
COGT	COGENT BIOSCIENCES INC	United States	$678.55M	103,913,396	87.38%	11.29%	Net Buying	Net Buying
ELDN	ELEDON PHARMACEUTICALS INC	United States	$38.96M	24,813,130	23.14%	76.86%
RAPT	RAPT THERAPEUTICS INC	United States	$279.77M	34,797,702	66.33%	33.67%	Net Selling
TSBX	TURNSTONE BIOLOGICS CORP	United States	$62.14M	23,099,335	46.24%	53.76%	Net Buying
ADTX	ADITXT INC	United States	$3.91M	1,665,214	0.09%	99.91%	Net Selling
EWTX	EDGEWISE THERAPEUTICS INC	United States	$1.46B	93,110,623	84.23%	15.77%	Net Buying	Net Buying
IMVT	IMMUNOVANT INC	United States	$4.13B	145,292,970	44.81%	55.19%	Net Buying	Net Selling
COYA	COYA THERAPEUTICS INC	United States	$119.83M	14,542,579	19.41%	14.62%	Net Buying
GDTC	CYTOMED THERAPEUTICS LTD	Singapore	$23.87M	11,529,328	0.04%	57.50%
VKTX	VIKING THERAPEUTICS INC	United States	$6.68B	100,488,339	75.97%	9.93%	Net Selling	Net Selling
NNVC	NANOVIRICIDES INC	United States	$13.66M	11,779,000	2.27%	97.73%
VIGL	VIGIL NEUROSCIENCE INC	United States	$107.70M	36,884,712	44.03%	55.97%	Net Buying
GOVX	GEOVAX LABS INC	United States	$3.17M	2,172,272	1.21%	98.79%	Net Buying	Net Buying
NMRA	NEUMORA THERAPEUTICS INC	United States	$1.66B	158,886,101	21.44%	78.56%	Net Buying
CARM	CARISMA THERAPEUTICS INC	United States	$70.21M	41,542,534	21.66%	74.42%
XERS	XERIS BIOPHARMA HOLDINGS INC	United States	$250.01M	140,453,467	42.66%	15.51%	Net Buying	Net Buying
ATHE	ALTERITY THERAPEUTICS LTD	Australia	$11.27M	2,802,360,380	0.00%	0.00%
ZURA	ZURA BIO LTD	United States	$136.45M	43,593,678	27.84%	72.16%	Net Selling
IRON	DISC MEDICINE INC	United States	$747.34M	24,681,028	44.57%	55.43%	Net Selling	Net Selling
ONCT	ONCTERNAL THERAPEUTICS INC	United States	$26.49M	2,959,645	13.07%	86.93%	Net Selling	Net Buying
INTS	INTENSITY THERAPEUTICS INC	United States	$54.01M	13,709,377	0.00%	14.63%
IVVD	INVIVYD INC	United States	$295.67M	119,221,230	37.84%	62.16%	Net Selling	Net Selling
SRRK	SCHOLAR ROCK HOLDING CORP	United States	$1.07B	77,866,281	60.56%	39.44%	Net Buying	Net Selling
OLMA	OLEMA PHARMACEUTICALS INC	United States	$598.85M	55,914,741	71.71%	28.29%	Net Buying	Net Selling
LXEO	LEXEO THERAPEUTICS INC	United States	$326.96M	26,668,956	60.65%	25.62%	Net Buying

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 52 points higher than the biotech industry average of 23. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -29.71% over the past year, underperforming other biotech stocks by -4 percentage points.

Incyte has an average 1 year price target of $73.92, an upside of 40.21% from Incyte's current stock price of $52.72.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Incyte, 25% have issued a Strong Buy rating, 16.67% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)

Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 47 points higher than the biotech industry average of 23. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -12.47% over the past year, overperforming other biotech stocks by 13 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $37.33, an upside of 27.9% from Harmony Biosciences Holdings's current stock price of $29.19.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Harmony Biosciences Holdings, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 16.67% have issued a Sell rating, and 16.67% have issued a Strong Sell.

3. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the third best biotech stock with a Zen Score of 66, which is 43 points higher than the biotech industry average of 23. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock lose -2.27% over the past year, overperforming other biotech stocks by 24 percentage points.

Voyager Therapeutics has an average 1 year price target of $20.50, an upside of 164.86% from Voyager Therapeutics's current stock price of $7.74.

Voyager Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Voyager Therapeutics, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 4 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Carisma Therapeutics (NASDAQ:CARM)

Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 13.98%.

Carisma Therapeutics's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)

Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 52.87%, which is 39 percentage points higher than the biotech industry average of 13.98%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Novo Nordisk A S (NYSE:NVO)

Novo Nordisk A S (NYSE:NVO) has an annual dividend yield of 1.1%, which is -13 percentage points lower than the biotech industry average of 13.98%. Novo Nordisk A S's dividend payout is not stable, having dropped more than 10% eight times in the last 10 years. Novo Nordisk A S's dividend has shown consistent growth over the last 10 years.

Novo Nordisk A S's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks down?

Biotech stocks were down -1.09% in the last day, and down -5.43% over the last week. Dare Bioscience was the among the top losers in the biotechnology industry, dropping -41.65% yesterday.

Dare Bioscience shares are trading lower after Brookline Capital downgraded the stock from Buy to Hold.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Royalty Pharma (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Royalty Pharma has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Royalty Pharma's stock has dropped -24.48% in the past year. It has overperformed other stocks in the biotech industry by 1 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 85 points higher than the biotech industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has dropped -2.27% in the past year. It has overperformed other stocks in the biotech industry by 24 percentage points.

3. Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 71 points higher than the biotech industry average of 15. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -29.71% in the past year. It has underperformed other stocks in the biotech industry by -4 percentage points.

Are biotech stocks a good buy now?

49.13% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 85.39% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 15.83x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.